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Background: The mechanisms by which sodium channel blockade and high-rate pacing modify 
electrogram substrates of Brugada syndrome (BrS) have not been elucidated.  
Objectives: To determine the effect of ajmaline and high pacing rate on the BrS substrates. 
Methods: Thirty-two BrS patients (age 40 ± 12 years) with frequent ventricular fibrillation (VF) 
episodes underwent right ventricular outflow tract (RVOT) substrate electroanatomical and 
electrocardiogram imaging (ECGI) mapping before and after ajmaline administration and during 
high-rate atrial pacing. In 4 patients, epicardial mapping was performed using open thoracotomy 
with targeted biopsies.  
 Results: Ajmaline increased the activation time delay in the substrate (33%; p = 0.002), ST 
elevation in the right precordial leads (74%; p < 0.0001), and the area of delayed activation 
(170%; p < 0.0001), coinciding with increased substrate size (75%; p < 0.0001). High atrial 
pacing rate increased the abnormal electrogram (EGM) duration at the RVOT areas from 112 ± 
48 to 143 ± 66 ms (p = 0.003) and produced intermittent conduction block and/or excitation 
failure at the substrate sites, especially after ajmaline. Biopsies from the 4 patients with 
thoracotomy showed epicardial fibrosis where EGMs were normal at baseline but became 
fractionated after ajmaline. In some areas, local activation was absent and unipolar EGMs had a 










Conclusions: INa reduction with ajmaline severely compromises impulse conduction at the BrS 
fibrotic substrates by producing fractionated EGMs, conduction block, or excitation failure, 
leading to the Brugada ECG pattern and favoring VF genesis. 

























Sodium channel blockers (e.g., ajmaline, procainamide, flecainide) can unmask the 
typical coved type of ST elevation (STE) in the right precordial leads of BrS patients1. However, 
how these drugs unmask the Brugada pattern and adversely affect the BrS substrate has not been 
clearly elucidated. An in-silico model has demonstrated that sodium current (INa) reduction 
creates activation block at sites of the current to load mismatch, leading to distal activation 
failure, local monophasic electrograms (EGM), and the typical ST-segment changes2. This study 
aims to determine the effect of INa reduction by ajmaline and/or fast pacing rate on the RVOT 




 BrS patients who had recurrent implantable cardioverter-defibrillator (ICD) discharges 
from VF episodes were enrolled into the study. All patients provided written informed consent, 
which had been approved by the Internal Ethics Review Board.   
 
Study Protocol 
The patients first underwent electroanatomical mapping of the BrS epicardial substrates using a 
ThermoCool catheter (Biosense Webster, Inc., Diamond Bar, CA) mapping/ablation catheters 
during sinus rhythm before and after ajmaline administration followed by electrophysiology 









of the study patients also underwent atrial pacing, either from the coronary sinus or high right 
atrium, with a decremental interval of 750, 600, 500, and 450 or 400 ms for 30 seconds or until 
Wenckebach periodicity or second-degree atrioventricular (AV) block occurred. During pacing, 
the mapping catheter was positioned at the RVOT substrate sites where fractionated EGM 
durations and late potentials were measured at baseline, pacing, and after ajmaline. 
 When non-invasive ECG imaging (ECGI; CardioInsight System, Medtronic, Inc., 
Minneapolis, MN) became available in our institutions, we added ECGI mapping for the 
arrhythmogenic substrates in our study protocol during baseline and after ajmaline infusion.  
Mapping 
 Detailed epicardial and endocardial mapping of arrhythmogenic substrate of the RV as 
well as epicardial mapping of the left ventricle was performed during sinus rhythm. First, 
epicardial and endocardial electroanatomical mapping was performed using the voltage map 
software on the CARTO Navigation System (Biosense Webster, Inc.). An abnormal BrS 
substrate area was characterized by abnormal fractionated EGMs. Once identified, these areas 
were tagged on the electroanatomical map. After the baseline map was obtained, intravenous 
ajmaline was administered (10 mg/min) until a maximal target dose of 100 mg. Mapping of the 
BrS substrates was then repeated. We defined arrhythmogenic substrate sites as areas that 
harbored fractionated-EGMs, which were defined as ECGs that had: 1) low voltage (≤1 mV); 2) 
split EGMs or fractionated-EGMs with multiple potentials with ≥2 distinct components, with 
>20 ms isoelectric segments between peaks of individual components; and 3) wide duration (≥70 
ms) of late potentials, with distinct potentials extending beyond the end of the QRS complex. 










Four patients underwent the study during an open thoracotomy because they had 
pericardial adhesion precluding percutaneous access into the pericardium. After the anterior 
RVOT epicardium was exposed and clearly visualized, point-to-point mapping was used over 
these areas, in which numbers were assigned over a grid of the anterior RVOT and RV 
epicardium. A ThermoCool catheter was used for mapping and ablation. Mapping was 
performed at baseline and after ajmaline administration both during sinus rhythm and atrial 
pacing at the left atrial appendage. A biopsy also was performed at the sites where fractionated 
EGMs were recorded.  
ECGI Mapping 
ECGI methodology has been described previously4-6 and is presented in detail in the 
Supplemental Text 1. Activation mapping was performed during sinus rhythm at baseline and 
after ajmaline administration. The method of reconstruction of the epicardial activation pattern is 
also detailed in Supplemental Text and Supplemental Figure 1. We measured maximum STE and 
minimum voltage of unipolar ECG within the late activation zone before and after ajmaline. 
Radiofrequency Ablation 
 Radiofrequency ablations were performed with power from 20-50 W, and the maximum 
temperature was set at 45°C. The primary end point during ablation was the elimination of the 
arrhythmogenic fractionated ECGs that were identified both during baseline and after ajmaline.  
Clinical End Points and Follow-up 
 All patients were followed up at 1 month after the ablation session and every 3 months 










term end points were death and VF episode(s), as detected by ICD interrogation and presence of 
Brugada ECG pattern.  
Data and Statistical Analysis 
Paired student t-test was used to compare baseline and ajmaline conditions. Fisher exact 
test or Chi-square test was used for categorical data wherever appropriate. All data were 
analyzed with a statistical package, SAS version 9.2. 
Results 
Our 32 study patients were highly symptomatic with frequent ICD discharges due to VF 
(Table 1); 28 underwent mapping and ablation percutaneously and the remaining 4 via 
thoracotomy.  
Effects of Pacing and Ajmaline on ECG Variables, ECG Duration, and Conduction 
Fractionated EGMs were recorded in all patients at the anterior RVOT epicardium and in 
12 of the 32 patients (37%) in both anterior and inferior RV epicardium. Ajmaline increased the 
substrate size from 13.8 ± 6.2 cm2 to 24.2 ± 8.6 cm2 (p = 0.0012). 
In general, higher atrial pacing rate uniformly increased the EGMs duration but the effect 
was moderate in the majority of the patients and quite large in the 2 patients  (Supplemental 
Figure 2) who had the longest baseline EGMs durations. Fractionated EGM duration increased at 
a higher atrial pacing rate: At 750 ms, the fractionated-EGMs were 112 ± 48 ms and increased to 
143 ± 66 ms (p = 0.003), measured during the shortest cycle length pacing that produced one-to-
one AV conduction. Figure 1 shows an example of the effect of pacing cycle length on the 










baseline (Figure 1A) and between 600 ms pacing at baseline and after ajmaline (Figure 1B). The 
bipolar EGMs recorded from the distal (ABLd) and proximal (ABLp) pair electrodes of the 
ablation catheter at the RVOT epicardium show fractionated-EGM potentials beyond the QRS; at 
baseline, the duration of the fractionated EGMs recorded from ABLd increased from 181 during 
pacing at 600 to 280 ms during pacing at 450 ms. Even during these remarkable changes in the 
EGM fractionation, there was no Brugada ECG pattern appearance until ajmaline administration 
(50 mg) and pacing at 600 ms cycle length (Figure 1B) which shows a profound effect of 
ajmaline on conduction: The bipolar EGMs recorded at the same RVOT epicardial site show the 
drug caused a further marked increase in conduction delay and conduction block, as shown by 
prolonged fractionated EGMs beyond the T wave, resulting in a variable increase in EGM 
duration ranging from 230 to 320 ms. The loss of amplitude of the bipolar EGMs of the last three 
complexes recorded from both ABLd and ABLp pairs (vertical arrows) is compatible with local 
activation failure (a long recording of  600 ms pacing after ajmaline is shown in the supplemental 
Video 1a & 1b to authenticate that the loss of EGMs amplitude were due to loss of excitation and 
not due to the loss of mapping catheter’s contact). Note that lead V2 shows alternation of the ST-
segment amplitude in such a way that the higher amplitude of the ST-segment was related to 
excitation failure and absence of local activation. Loss of amplitude of fractionated EGMs upon 
ajmaline administration of high-rate pacing was observed in 11 of 15 patients (73%).  
Table 2 summarizes the effect of ajmaline on the ECG variables: Ajmaline increased the 
QRS duration by 22% (95% confidence interval [CI]: 7.5-37.7%; p < 0.0001); PR interval 18% 
(95% CI: 12.5-24%; p < 0.0001); QTc interval 8% (95% CI: 3-12.6%; p = 0.001); and ST-
segment in the right precordial leads by 74% (95% CI, 74-161%; p < 0.0001).  










Figure 2 shows an example of ECGI maps from one of our patients (panel A) and 
compares 4 ECGI variables in the late activation zone: activation time, STE, voltage, and area of 
late activation zone, at baseline and after ajmaline infusion during sinus rhythm in 20 patients. 
Panel A demonstrates that ajmaline increases the activation time, STE, and area of the late 
activation zone, while reducing the EGM voltage in one of the study patients. In aggregate 
(Figure 2, panel B), ajmaline delayed the activation time (33%; p = 0.003) and increased local 
unipolar STE (70%; p = 0.002), while significantly reducing the voltage (unipolar) in the late 
activation zone (33.5%; p = 0.016).  
Fibrosis and Fractionated EGMs in Direct Epicardial Mapping 
Figure 3 shows an example of how ajmaline unmasked the arrhythmogenic substrate 
areas on the underlying anterior RVOT epicardium in a patient who underwent epicardial 
mapping during a thoracotomy. Ajmaline (30 mg IV) caused changes in bipolar and unipolar 
EGMs of areas 3, 8, and 13 from relatively normal EGMs to markedly abnormal fractionated 
EGMs, coinciding with an appearance of STE in the unipolar EGMs in these areas. In particular, 
the unipolar EGMs after ajmaline infusion have a monophasic morphology (resembling an action 
potential), especially at panels B, E, and G. This is a sign of absence of local activation (similar 
to that recorded from a monophasic action potential catheter)7. This phenomenon is present at 
sites 3, 8, and 13. Biopsies at sites 8 and 13 and their histology demonstrate marked epicardial 
fibrosis (panel D). 
All 4 patients, whose mapping and ablation were done under open thoracotomy, had 
localized epicardial and interstitial fibrosis, which is associated with abnormal fractionated 










thought to be a normal area of RVOT epicardium because of a normal EGM at baseline, but the 
drug could also cause excitation failure and asynchronous conduction in the substrate areas, as 
shown in Figure 4. 
Figure 4A shows lead avF, and local bipolar and unipolar EGMs recorded from the 
RVOT epicardium of another patient who underwent open thoracotomy. The bipolar EGMs 
recorded from the distal and proximal pair electrodes (ABLd and ABLp) and the unipolar EGM 
recorded from the distal electrode of the ablation catheter (ABLd uni) show prolonged 
fractionated EGMs at baseline. After ajmaline, the EGMs’ duration drastically changed and 
became markedly delayed with multiple components and with the EGM duration of 350 and 305 
ms at the ABLd and ABLp recording sites, respectively. The unipolar recording of the distal 
electrode of the 1st complex also showed multiple potentials, suggesting zig-zag conduction at 
the subepicardial tissue below the recording epicardial site. These late potentials were absent in 
the 2nd complex, indicating the conduction block at the subepicardial site; as a result, the ABLd 
uni of this complex also had a monophasic component (indicated in red).  
 Figure 4B shows the recording of another RVOT substrate site of the same patient. At 
this site, delayed conduction, asynchronous activation, and intermittent conduction blocks were 
demonstrated. The duration of fractionated EGMs at these sites was variably and markedly 
lengthened with intermittent conduction block causing a significant degree of dispersion of 
conduction between the distal and proximal pairs. Excitation failure was also seen between the 
distal and proximal pairs. Comparison with complexes 1 and 5 shows that these waves are 
distinct from the local T waves. When conduction blocks occurred in the distal pair of bipolar 
recording, monophasic components emerged in the unipolar EGMs. Biopsy at this site revealed 











After one ablation procedure, type 1 Brugada ECG pattern disappeared in all but 2 patients who 
had Brugada ECG pattern after ajmaline. After a mean follow-up period of 50 ±18 (median 48) 
months, 31 of the 32 patients had no VF recurrence; the remaining patient with VF recurrence 
had concomitant J-wave elevation in the inferior leads, hence a combined syndrome of BrS and 
the early repolarization pattern. The patient is expected to be scheduled for repeat ablation. The 2 
patients who continued to have type 1 Brugada ECG pattern had no VF recurrence.  
Discussion 
Our study provides new insights into how ajmaline unmasks the Brugada ECG pattern: 
The drug, by reducing INa, markedly delays impulse conduction in these RVOT substrate sites 
that have underlying fibrosis, thereby increasing the areas of the late activation and in turn 
increasing STE over the right precordial ECG leads. This is associated with local STE and local 
loss of amplitude of the unipolar EGMs, as detected by ECGI. Furthermore, ajmaline unmasks 
the substrate by creating excitation failure, showing as the genesis of monophasic EGMs or as 
late monophasic components of unipolar EGMs in fibrotic tissue (Figure 3). In short, when INa is 
reduced, by rapid pacing or ajmaline administration, impulse conduction in the RVOT epicardial 
fibrotic substrate sites is severely compromised. This causes asynchronous conduction, 
conduction block, and/or excitation failure, leading to loss of local activation at these sites. These 
electrophysiologic derangements are the underlying mechanism of the STE in the right 












Conduction Abnormalities After High Atrial Pacing Rate 
The duration of fractionated EGMs was significantly further prolonged when atrial rate 
increased in all patients. The increased EGM duration after shortening of the pacing cycle length 
suggests a further increase in conduction abnormality, a well-known frequency-dependent 
response of conduction in the diseased tissue8,9.  
Unmasking the Brugada ECG by Ajmaline  
Epicardial and interstitial fibrosis was found in all 4 patients who underwent open 
thoracotomy for mapping, surgical radiofrequency ablation, and subsequent study of the 
biopsies. The EGMs at the sites where fibrosis was present could be relatively normal, as shown 
in Figure 3; they only became markedly abnormal after ajmaline. In some areas, conduction 
block or asynchronous conduction occurred along with the appearance of the Brugada ECG 
pattern. Remarkably, monophasic unipolar EGMs were recorded after ajmaline administration as 
a sign of absence of activation, even though the tissue was intrinsically excitable. This is in line 
with the in silico and experimental observations of Hoogendijk et al.10 and that of Vigmond et 
al.11, who show that monophasic-like local electrograms at the epicardial side of the RVOT could 
be recorded as a result of current-to-load mismatch owing to structural abnormalities.   
Figure 5 displays the mechanisms causing monophasic EGMs during excitation failure. 
The figure duplicates the first two complexes from Figure 4. Complex 1 shows a local 
fractionated unipolar EGM with local ST-elevation in ABLd-uni with an appearance of a small 
monophasic complex. This is caused by myocardium under the electrode ABLd-uni that was not 
activated, leaving the membrane potentials at the resting potential. Since this myocardium is 









when the surrounding myocardium depolarizes. This means the myocardium at electrode ABLd-
uni will receive intracellular current that is transferred to the extracellular space where it can be 
recorded as a positive potential (monophasic action potential) with shape of the transmembrane 
potential of the surrounding myocardium. In complex 1, the amplitude of the local unipolar EGM 
(or monophasic complex) is small, but still looks like a V1 of type 1 Brugada pattern. In the 
complex 2, a larger part of the myocardium located at ABLd-uni is not activated during the first 
activation wave “a” but the myocardium under the proximal pair is activated late by activation 
wave “d”. The late activated myocardium at ABLp-uni will provide the intracellular current that 
flows to the myocardium at ABLd-uni and give rise to a monophasic complex in the extracellular 
space recorded at ABLd-uni. 
Even though abnormal fractionated EGMs were present at the anterior RVOT in all our 
patients, many patients initially did not have a spontaneous type 1 Brugada ECG pattern. Thus, 
localized fractionation and late conduction at the RVOT alone may not be enough to cause the 
type 1 Brugada ECG pattern. The signature Brugada ECG pattern appeared only after ajmaline 
was administered in many of our patients and monophasic unipolar EGMs were recorded. This 
was associated with further prolongation of these abnormal epicardial EGMs and conduction 
block or excitation failure, as shown in Figure 1. Clearly, conduction block in various areas of 
the anterior RVOT epicardial substrate sites was instrumental in unmasking the type 1 Brugada 
ECG pattern. This is supported by the observation that small changes in activation contributed to 
subtle changes in the ECG ST-segment. 
 These findings support those of Hoogendijk and colleagues,10 as well as ten Sande et 
al.,12 which suggest that, subepicardial structural abnormalities (in our study BrS patients, subtle 










barriers that create the tortuous path through which the propagating impulses have to go, and in 
turn create fractionated-EGMs and late potentials; these fibrotic tissues may also create a narrow 
isthmus for the depolarizing current to travel through and then reach the area of large expansion 
of the myocardium mass where “current-to-load mismatch” occurs, especially in the presence of 
reduced INa by ajmaline, causing excitation failure. The excitation failure can be intermittent or 
cycle length dependent, resulting in intermittent loss of local activation. The combined tissue 
discontinuity, excitation failure, and loss of local activation lead to the presence of STE in the 
right precordial leads because of the electronic current generated by activation of the proximal 
site through the isthmus.  
This observation is therefore consistent with previous studies. In a study of an explanted 
heart of a BrS patient who had recalcitrant electrical storms necessitating heart transplantation 
surgery, Coronel et al. found abundant fibrous and adipose tissue in the RV associated with 
marked activation delay in the RV13. Our recent collaborative multicenter study unequivocally 
demonstrated epicardial and interstitial fibrosis and reduced gap junction expressions in the 
RVOT of sudden cardiac death victims with BrS family history and negative routine autopsy14. 
In the same study, we also found epicardial and interstitial fibrosis from the biopsies taken from 
BrS patients during open-heart ablation from RVOT epicardial sites; at these sites, abnormal, 
fragmented, and delayed conduction were also found14. Thus, the above observation 
incontrovertibly support that RV epicardium is the main substrate site where fractionated late 












Study Limitations:  
Our study patients were highly selective of symptomatic patients and only 3% of our 
patients had SCN5A pathogenic variants, thus our study population may not be representative of 
general BrS population. Our GWAS study shows that SCN5A in Thai BrS population is only 
7%16. However, we share the same findings as those of the Europeans’ and Japanese’s that BrS 
phenotype in our population is associated with polygenic variants including SCN5A, Hey2 and 
SCN10A16. Thus, we believe that our population is a not a unique subset.   
The number of patients (n = 4) in this study who underwent biopsy of the RVOT 
substrate sites is relatively small. It is conceivable that not all BrS patients may have extensive 
fibrosis, as witnessed in our 4 study patients. However, we have so far studied 4 other patients 
who underwent open thoracotomy (not included in this study); they all had epicardial and 
subepicardial fibrosis. Thus, it is very likely that most BrS patients had subtle RV fibrosis as the 
primary underlying pathology and that our clinical observation of reduced INa is very likely 
applicable to BrS. However, since our study patients are highly symptomatic, the degrees of 
conduction abnormalities and fibrosis in asymptomatic patients may not be as severe as observed 
in our study patients. Indeed, it would be interesting to carry out studies to determine the 
relationship between the magnitude/severity of these abnormalities and the incidence and 
severity of VT/VF occurrences in BrS patients.    
Conclusions: 
Our study clearly shows that INa reduction with ajmaline and/or high rate pacing severely 
compromises impulse conduction in the BrS substrates and can uncover the fibrotic sites by 










current-to-load mismatch phenomenon that leads to VF genesis and the signature Brugada ECG 
pattern. Ajmaline also is useful in guiding catheter ablations to eliminate all arrhythmogenic 
areas, as evidenced by a two-fold increase in the size of the target area for the ablation. Thus, 
using sodium channel blockers, ajmaline, or pilsicainide is an invaluable tool to guide catheter 
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Figure Legends  
Figure 1. The effects of pacing and ajmaline on the BrS substrate sites are illustrated (see 










450 ms (coronary sinus pacing) on the electrogram duration at the RVOT epicardial substrate 
site. Figure 1B shows a conduction block at the same site as Figure 1A, after ajmaline during 
pacing at 600 ms. V2 IC3 = Lead V2 at the 3rd intercostal space. ABLd = ablation distal pair 
electrodes; ABLp = ablation proximal pair electrodes; RVAp = right ventricular apex proximal 
pair electrodes; Stim = stimulation artefact.  
Figure 2. Panel A shows an example of ECGI maps from one of the study patients, displaying 
activation time, ST elevation (STE), voltage, and areas of the late-activated area before and after 
ajmaline during sinus rhythm. Panel B summarizes results from the analyses of all patients 
within the late activation zone.  
Figure 3. Computed tomography scan of the heart (center) from 1 of the 4 BrS patients 
undergoing open thoracotomy mapping and ablation showing RV anatomical grid. ECG lead II 
and a distal bipolar (0.4 mV/cm voltage scale at the filter 30 Hz-300 Hz) and unipolar 
electrogram (5 mV/cm voltage scale at the filter 0.05 Hz-300 Hz) are displayed in insets of the 
surrounding panels. Clockwise from the right are panels A and B, which display electrograms 
from site 8 at baseline and after ajmaline, respectively; panel C shows electrograms recorded 
from site 9 after ajmaline; panel D is histology of the biopsy specimen (Masson’s trichrome 
stain) from site 8 showing epicardial fibrosis; panels E and F and panels G and H display 
electrograms recorded from sites 13 and 3 after ajmaline and at baseline, respectively (see text 
for details). 
Figure 4.  Figures 4A and 4B show ajmaline produced delayed conduction, asynchronous 
activation, and conduction block causing monophasic appearance of the unipolar recording at 










the biopsy from this recording site and shows marked epicardial fibrosis and early fibrotic 
replacement of the myocardial at this site (orange arrow). 
Figure 5. A schema to explain how ajmaline delayed conduction and caused excitation failure of 













Table 1. Patient Clinical Characteristics 
Number of patients 32 
Age 40 ± 12 (median 37) years 












Aborted cardiac arrests/VF = 30 (94%) 
Syncope = 2 (6%) 
Family history  10 (31%) 
Spontaneous Brugada ECG pattern  28 (88%)  
Distribution of patients according to total 
number of VF episodes on ICD 
 
No episode = 4 (12%) 
1-4 episodes = 6 (19%) 
5-9 episodes = 2 (6%) 
10-20 episodes = 5 (16%) 
>20 episodes = 15 (47%) 
SCN5A mutation (only 29 had completed 
genetic study 
1 of 29 (3%) 




























% Difference from 
baseline (95% CI) 
P 
Value 
CCL (msec) 923 ± 180  884 ± 171 -4.2% (-3% to 11.5%) 0.241 
PR (msec) 176 ± 31  208 ± 38  18% (12.5% to 24%) <0.0001 
QRS (msec) 106 ± 22  130 ± 44  22.6% (8% to 38%) 0.005 
QTc (msec) 415 ± 44 449 ± 49 8% (3% to 12.6%) 0.001 
ST-seg (mV) 0.31 ±0.19  0.54 ± 0.26 74% (45% to 161%) <0.0001 
RVOT-subs 13.7 ± 5.9 23.9 ± 8.2 74% (58% to 91%) <0.0001 
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